Portfolio Rapha Capital Management

3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

By Kevin SlawinNovember 19, 2019July 14th, 2021No Comments

3D Bio Therapeutics, Inc.
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
November 19, 2019

Previous Post3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
Next PostPoseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions